Novel Drug for Rare Chronic Liver Disease Wins Conditional FDA Approval

Source link :

The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome proliferator-activated receptor (PPAR) agonist, elafibranor is indicated in combination with ursodeoxycholic acid (UDCA) for patients with an inadequate response to UDCA, or as monotherapy for those unable to tolerate […]

Author : News Health

Publish date : 2024-06-11 15:09:58

Copyright for syndicated content belongs to the linked Source.